BI-2493 is a structural analogue of BI-2865 and a highly selective and orally active pan-KRAS inhibitor. BI-2493 can attenuate tumor growth. BI-2493 can be used for cancer iseases research.
BI-2493 (0-10 μM, 72 h) inhibits the proliferation of KRAS mutant cancer cell lines in a concentration-dependent manner[1].
BI-2493 (90 mg/kg, p.o., twice daily for 21 days) exhibits tumor-suppressive activity in LS513/GP2d/HPAC/SW620/MIAPACA2-derived xenograft NMRI mice models[1].
References:
[1]. Kim D, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023 Jul;619(7968):160-166.
















